Decades of research brought us here: a breakthrough treatment for patients with glioblastoma

The Need

For decades, glioblastoma care has had to focus on hope. Patients and patients’ loved ones need neurosurgeons, neurologists, scientists, and entrepreneurs to provide a treatment option that will stop tumor regrowth once and for all.

per patient cost

# 1

month average life expectancy after diagnosis

0

patients live 5 years after diagnosis

0 %

patients a year diagnosed

0

It is nearly guaranteed that glioblastoma will recur. This is because residual brain cancer stem cells, the source of tumor regrowth, survive any existing treatment. So, the key to stopping tumor regrowth is destroying the brain cancer stem cells.

No treatment exists that can do this, until now.
_________

The Science

By discovering a way to target brain cancer stem cells, we've created an innovative nanomedicine specifically designed to prevent tumor growth: a fundamentally different approach that will positively transform patient outcomes.

Our nanomedicine is a transformational breakthrough and the beginning of the next generation of stem cell and gene therapy to treat brain diseases.

Our Platform

For years, each of us dedicated our careers to brain cancer in our own way. Shared values of scientific excellence, patient-centered innovation, and empathy brought us together at Johns Hopkins, and has created what is now Dome.

Our mission is to increase the life expectancy of patients with any brain disease, starting with a cure for glioblastoma.

Beyond therapeutic innovation, we are proud to support the Mission:Brain Foundation, a global non-profit dedicated to providing neurosurgery care to underserved regions.

The Team

Dr. Alfredo Quiñones-Hinojosa, also known as “Dr. Q”, serves as Chairman of the Department of Neurological Surgery and is the Dean of Research. He leads the Brain Tumor Stem Cell Laboratory at Mayo Clinic Florida, where he has been recognized with the distinction of the William J. and Charles H. Mayo Endowed Professorship.

Dr. Quiñones-Hinojosa earned his B.A. in psychology from the University of California– Berkeley and his M.D. from Harvard Medical School, where he graduated cum laude. He completed his neurosurgery residency and a postdoctoral fellowship in developmental and stem cell biology at the University of California, San Francisco. His career as a neurosurgeon started at Johns Hopkins University in Baltimore, where he was promptly named as Professor of Neurosurgery and Oncology and served as the director of the Brain Tumor Program.

Dr. Quiñones-Hinojosa’s practice focuses on the treatment of primary and metastatic brain tumors. He is a world-renowned leader in brain mapping techniques utilized to safely remove tumors close to eloquent brain regions and in minimally invasive endoscopic approaches required to operate on difficult-toreach skull base tumors. Dr. Q uses his laboratory as an extension of the operating room, and together with his team of scientists, they look to better understand and elucidate multiple molecular drivers of brain cancer migration, invasion, metabolism, and determinants of the tumor microenvironment. He also performs translational and clinical research. For instance, Dr. Quiñones-Hinojosa team has one active clinical human protocol to maximize the extent of resection in the operating room and several approved protocols to conduct our work in rodents, primates, and humans. One of the other current clinical projects involves using mesenchymal stem cells for the treatment of glioblastoma.

Dr. Quiñones-Hinojosa has written seven books about brain cancer and neurosurgery that have been translated to multiple languages. He has published over 500 peer-reviewed publications and currently holds an H-index of 80. His research is supported by the National Institute of Health (NIH), where he also serves as reviewer in many NIH study sections such as the Clinical Neuroimmunology and Brain Tumors (CNBT).

Over the last 15 years, Dr. Quiñones-Hinojosa has mentored more than 300 post-graduate students and neurosurgery residents, who are currently working in prestigious institutions of the United States such as Harvard, Johns Hopkins, MD Anderson, UCSF, as well as other institutions around the world in Mexico, Spain, Panama, England, and many others.

Dr. Quiñones-Hinojosa has received many honors and awards in recognition of his work. He has been named one of the 100 most influential Hispanics in 2008, as the recipient of the Gary Lichtenstein Humanitarian Award and Neurosurgeon of the Year in 2014, and one of Mexico’s most brilliant minds in the world by Forbes Magazine in 2015. Dr. Quiñones-Hinojosa is the recipient of the prestigious Charles B. Wilson Award granted by the Congress of Neurological Surgeons (CNS) in 2021 due to his meritorious career in neurosurgery, and also serves as the current International Vice-chair of the AANS/CNS Tumor Section. Dr. Quiñones-Hinojosa has also received multiple honoris causa degrees from several institutions around the globe, including Southern Vermont College, Lackawanna College, Dominican University, University of Notre Dame, Loyola University, and others countries like Mexico, Ecuador, and Peru. Apart from his clinical and research activities. He is the co-founder and president of the non-profit organization Mission:BRAIN (Bridging Resources and Advancing International Neurosurgery; www.missionbrain.org) and a member of the executive committee of Voices Against Brain Cancer. He has also founded three companies to extend the reach of his discoveries to more patients and has filed more than 25 patents with the same purpose.

Dr. Quiñones-Hinojosa has published his inspirational autobiography, “Becoming Dr. Q,” which verses on his journey from a migrant farmworker to a neurosurgeon. Part of Dr. Quiñones-Hinojosa life was included in the 2009 Peabody Award-winning ABC TV Series “Hopkins” and the 2021 EMMY/ BAFTA Award-winning show “The Surgeons Cut,” produced by the BBC/Netflix. Disney and Plan B Entertainment productions announced that his inspirational life story will also be featured in theaters.